Highlights
- Qcide® approved by OMRI as a Botanical Pesticide under the USDA National Organic Program.
- Listing enables use of OMRI Listed® seal, confirming suitability for certified organic production.
- Organic approval expands potential applications in crop protection, consumer pest control, and public health.
Bio-Gene Technology Limited (ASX:BGT), an Australian developer of natural insecticides, announced that its product Qcide® has been evaluated by the Organic Materials Review Institute (OMRI) in the USA and listed as a Botanical Insecticide under the USDA National Organic Program (USDA NOP).
OMRI is a non-profit organisation that reviews products for compliance with organic production standards. Qcide® has been approved as a botanical pesticide suitable for crop pest, weed, and disease control, and has been recognised as a 100% natural, non-synthetic plant extract derived from Eucalyptus cloeziana.
OMRI Listing and Organic Compliance
The listing allows Bio-Gene to include the OMRI Listed® seal on Qcide® marketing and technical materials, providing recognition that the product can be used in certified organic production. The listing is classified as ‘Allowed with Restrictions’, requiring organic growers to apply preventive, mechanical, or physical pest management methods prior to using any pesticidal inputs.
The approval confirms Qcide®’s compliance with OMRI Standards, which are aligned with USDA NOP regulations (7 CFR Part 205). This listing does not impose any limitations on composition or purity, and Qcide® is accepted as fully natural and non-synthetic.
Also Read - AF Legal Group (ASX:AFL) Shares Jump 15% on Thursday. Here's Why.
Strategic Implications and Market Scope
The OMRI listing broadens the potential use of Qcide® across multiple applications, including organic crop protection, consumer pest control, and public health sectors. Bio-Gene plans to pursue similar organic product approvals in other jurisdictions, supporting the wider adoption of Qcide®-based formulations.
Share Performance of BGT
BGT was trading 21.42% higher at AUD 0.034 per share as of 14 November 2025 at the time of writing.






Please wait processing your request...